Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
grade B 12.01 1.78% 0.21
BCYC closed up 1.78 percent on Wednesday, September 18, 2019, on 5.12 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical BCYC trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
Doji - Bearish? Reversal 0.00%
Parabolic Rise Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%

Older signals for BCYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Medicine Health Biopharmaceutical Life Sciences Diseases Immunology Oncology Tumors Astrazeneca Immune Checkpoint
Is BCYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.91
52 Week Low 6.2401
Average Volume 20,423
200-Day Moving Average 0.0
50-Day Moving Average 8.1236
20-Day Moving Average 8.0628
10-Day Moving Average 8.988
Average True Range 1.088
ADX 33.68
+DI 45.5254
-DI 6.1061
Chandelier Exit (Long, 3 ATRs ) 10.8459
Chandelier Exit (Short, 3 ATRs ) 9.5041
Upper Bollinger Band 11.3
Lower Bollinger Band 4.8256
Percent B (%b) 1.11
BandWidth 80.299648
MACD Line 0.7807
MACD Signal Line 0.1925
MACD Histogram 0.5883
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.37
Resistance 3 (R3) 16.59 15.35 15.65
Resistance 2 (R2) 15.35 14.24 15.24 15.40
Resistance 1 (R1) 13.68 13.55 13.06 13.46 15.16
Pivot Point 12.44 12.44 12.13 12.33 12.44
Support 1 (S1) 10.77 11.33 10.15 10.56 8.86
Support 2 (S2) 9.53 10.64 9.42 8.62
Support 3 (S3) 7.86 9.53 8.37
Support 4 (S4) 7.65